[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pigmented-lesions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pigmented-lesions":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100439630","dermoscopy-augmented-histology-trial-a-randomized-controlled-trial-100439630",false,"NCT05004792","Dermoscopy Augmented Histology Trial, a Randomized Controlled Trial","Correlation Between Online Case-based Training of Pathologists in Dermoscopic Images and Diagnostic Accuracy in Histopathological Interpretation of Skin Lesions Suspicious of Melanoma","DAHT-RCT","Inclusion Criteria:\n\n* Pathologists are required to evaluate melanocytic lesions routinely\n* Doctors must be registered authorized health personnel\n* Access to a smartphone\u002Ftablet\u002Fcomputer with internet\n\nExclusion Criteria:\n\n\\- Assessment of less than 30 DAHT cases",true,"ALL",{"count":20,"type":21},258,"ESTIMATED","INTERVENTIONAL",[24],"NA","Pathologists provide the current gold standard in skin lesion diagnostics, most often primarily based on the interpretation of histological slides. Still, it has been suggested that pathologists' diagnostic accuracy and confidence could be improved if they gained access to additional clinical information and in-vivo clinical and dermoscopic images of melanocytic tumors. This study examines the effect of digital training for pathologists in interpreting dermoscopic and clinical skin tumor images.\n\nThis study aims to evaluate the impact of dermoscopy training on pathologists' assessment of melanoma-suspected skin lesions.\n\nData collection of DAHT cases: Department of plastic surgery, Herlev hospital, year 2020-2021,\n\nDAHT platform: Made in 2021-2023 by Melatech,\n\nConsensus agreement: Four dermatopathologists assess all DAHT cases, year 2023-2024\n\nEnrollment of pathologists: Randomization and assessment DAHT cases, year 2026.",[27,28],"Melanoma","Pigmented Lesions","NOT_YET_RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":21},"2026-08-13",{"date":37,"type":21},"2027-12-13",{"name":39,"class":40},"Herlev Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":17,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100566434","intense-pulsed-light-ipl-medical-device-as-treatment-for-patient-suffering-from-skin-disorder-100566434","NCT06655129","Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder","Post Market Clinical Study of an Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder","Anthelia","Inclusion Criteria:\n\n* Adult men or women\n* Excessive Hairiness:\n* Patient with unwanted hair on the body (legs, arms, bikini line, or axilla)\n* Patient over 18 years.\n* Patients with Fitzpatrick skin types from I to V.\n* Women were required to be post-menopausal, surgically sterilized, or under a medically acceptable form of birth control (i.e., oral contraceptives, IUD, contraceptive implant, or barrier methods with spermicide or abstinence) during the study time period.\n\nVascular lesions:\n\n* Patients over 18 years.\n* Patients with Fitzpatrick skin types from I to IV.\n* Patients with varicosities and Rosacea on the face or upper and lower limbs.\n\nPigmented lesions:\n\n* Patients over 18 years.\n* Patients with solar lentigines on their cheeks, back, hands, arm and leg (\\> 3 mm).\n* Patient with Fitzpatrick skin type from I to IV.\n\nAcne:\n\n* Patients over 18 years\n* Patients with Fitzpatrick skin types from I to IV.\n* Patients with facial acne vulgaris on face.\n* Willing to sun protect treated area for the duration of enrollment in the study and 4 weeks after treatment.\n\nExclusion Criteria:\n\n* Patients with history of malignant lesions or pre-malignant lesions, scarring, or infection in the area to be treated History of keloidal or hypertrophic scarring\n* Patients with a known photosensitivity\n* Pregnancy women\n* Patient with diabetes mellitus suntan in the area to be treated\n* Use of photo-sensitizing products for 7 days before treatment (selftanning lotions, activators, self-tanning shower gel, etc.)\n* Exposure to the sun or UV rays at least 4 weeks before the treatment and 1 week afterwards\n* Zones with uncovered tattoos, suspect spots or skin diseases (including spots, inflammation, beauty spots, tumors or melanomas, psoriasis, herpes...)\n* Use of medication that induces anticoagulative medication or thromboembolic condition\n* Patients with pacemaker or internal defibrillator\n* Patients that used of NSAIDS two weeks prior to or 2 weeks following the treatment\n* Epileptic patients\n* Additional criteria for excessive hair: Patients that use waxing or other methods of photo epilation within 1 month prior to treatment.\n* Additional criteria for acne: Patients currently under oral antibiotic or oral therapy for acne.","18 Years",{"count":51,"type":21},85,[24],"The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias. Since then, its favorable cost and versatility in contrast to many singlespectrum lasers, has led to its rapid proliferation and use in a number of different clinical settings. As described in the literature, ANTHÉLIA medical device is intended to treat skin disorders:\n\n* Excessive Hairiness (Hirsutism, Hypertrichosis...)\n* Vascular lesions (Rosacea….)\n* Pigmented lesions (Lentigo et melasma)\n* Acne vulgaris",[55,56,28,57],"Excessive Hairiness","Vascular Lesion","Acne Vulgaris","RECRUITING","2024-10-21",{"date":61,"type":33},"2024-10-23",{"date":63,"type":33},"2024-01-20",{"date":65,"type":21},"2025-12-01",{"name":67,"class":68},"Eurofeedback","INDUSTRY",5]